Creation of NICE
The National Institute for Clinical Excellence became a legal entity in April. Our aim was to create consistent guidelines and end rationing of treatment by postcode across the UK.Find out more about us
First NICE guidance
We published our first piece of guidance: a rapid assessment of flu product zanamivir.
First public board meeting
First technology appraisal
TA1 Guidance on the extraction of wisdom teeth (March).
National Collaborating Centres established
The National Collaborating Centres help develop clinical guidelines by using the expertise of the royal medical colleges, professional bodies and patient/carer organisations.
First interventional procedures guidance
IPG1 Uterine artery embolisation for fibroids (July).
The Health Development Agency (HDA) transfers to NICE
The HDA was a special health authority established in 2000 to develop the evidence base to improve health and reduce health inequalities.
It worked in partnership with professionals and practitioners across a range of sectors to translate that evidence into practice.
Health Development Agency publications can be found on the British Library Web Archive.
We changed our name to the National Institute for Health and Clinical Excellence.
First public meeting
The Interventional Procedures Advisory Committee held its first meeting in public in June.
Quality Outcomes Framework
We became responsible for developing and reviewing indicators for the Quality Outcomes Framework (QOF).
We were asked to develop indicators on behalf of the NHS Commissioning Board for the Clinical Commissioning Group Outcome Indicator Set (CCG OIS).
National Prescribing Centre (NPC) joins NICE
The NPC became part of NICE in April. The centre helped healthcare organisations to deliver safe and cost-effective medicines use for patients and the public. It later became the Medicines and Prescribing Centre.
NICE Pathways goes live
In May we launched an online tool providing quick and easy access, topic by topic, to our full range of guidance and tools.
First diagnostics guidance
DG1 The EOS 2D/3D imaging system (October).
NICE becomes a non-departmental public body
In April we changed our status from a special health authority to a non-departmental public body and became the National Institute for Health and Care Excellence. We also officially took on the work of bringing evidence-based guidance and standards to the social care sector, as outlined in the Health and Social Care Act 2012.
New Chair appointed
We welcomed a new Chair, Professor David Haslam, who took over from Professor Sir Michael Rawlins following his 14 years in the role.
The NHS Technology Adoption Centre joins NICE
The adoption team is responsible for identifying ways to overcome potential barriers to the implementation of NICE guidance.
First social care guideline
SC1 Managing medicines in care homes (March).
First medicines practice guideline
MPG1 Developing and updating local formularies (March).
First highly specialised technologies guidance
HST1 Eculizumab for treating atypical haemolytic uraemic syndrome (January).
First drug approved from old Cancer Drugs Fund
In July we approved bosutinib (Bosulif, Pfizer) which treats some people with chronic myeloid leukaemia (CML). It means the drug will become available through normal NHS funding channels where as previously it was only available through the Cancer Drugs Fund (CDF).
Unified indicator menu launched
We launched the unified NICE indicator menu for general practice and CCGs.
We published a guideline to educate the general public about how they can help fight the battle against antimicrobial resistance.
We also started a series of 30 management of common infection guidelines. Find out more on our antimicrobial prescribing guidelines page.
Physical and mental health in the workplace
In March we updated our quality standard promoting physical and mental health in the workplace.
500 hundred technology appraisals
In January, we published our 500th technology appraisal.
Cancer impact report published
We published NICEimpact cancer. A report that considers how our evidence-based guidance might contribute to improvements in the diagnosis and treatment of cancer. It’s the first of several impact reports looking at how the health and social care system uses our recommendations to improve outcomes in priority areas.